OHB's Two-Front Battle: A Billion-Euro Win Overshadowed by Rocket Delays and Profit-Taking

OHB's Iris² satellite contract fails to lift shares as Rocket Factory delays maiden flight, stock falls 18% below 50-day average.

The timing could hardly have been more awkward. Just as OHB SE celebrated its role in Europe's flagship Iris² satellite programme — a contract worth close to €1 billion — the company's rocket subsidiary delivered a dose of reality. Rocket Factory Augsburg, in which OHB holds a 65.1 percent stake, flagged technical problems encountered during pressure tests in late July, pushing back the maiden flight of its RFA One launcher. Management insists the first launch will still happen before year-end, but the admission has injected fresh uncertainty into a stock that was already struggling to hold its ground.

Investors, it seems, are in no mood to pay up for good news. The Iris² announcement initially lifted the share price, but those gains evaporated quickly. By Thursday's close, the stock had fallen 3.1 percent to €231.00 — a second source puts the session decline at 4.6 percent with a closing price of €229.50, reflecting the volatility of the day's trading. Either way, the pattern is unmistakable: the shares now sit roughly 18 percent below their 50-day moving average, a technical signal that the consolidation following a spectacular twelve-month rally is gathering force.

The Shape of Europe's Satellite Order Book

The Iris² contract award has clarified how the spoils of Europe's most ambitious space programme will be divided. OHB secured the higher-value segment — 18 satellites destined for medium Earth orbit, with a contract value approaching €1 billion and the first units slated for operational readiness in 2029. The cheaper low-Earth-orbit tranche went to Belgian startup Aerospacelab, which beat out Airbus in the SpaceRISE consortium's procurement process. Airbus, however, does not leave empty-handed: the group will build an additional 66 satellites for military communications.

For OHB, the allocation cements its role as a cornerstone supplier in the premium tier of Europe's space ambitions — precisely the narrative analysts have leaned on when justifying the company's long-term growth story tied to continental defence and space programmes.

A Pattern of Selling Into Strength

The market's muted response to Iris² is all the more striking given the run of positive headlines OHB has generated in recent weeks. The company was promoted to the SDAX just over a week ago, replacing Klöckner. Roughly two weeks before that, it delivered half-year results showing a 30 percent improvement in adjusted EBITDA margin. In between, it closed a capital increase raising €484 million in gross proceeds, earmarked for expanding manufacturing capacity and potential acquisitions — a move that lifted the free float to around 18 percent.

Yet each of these milestones has been met with selling. The stock has lost ground following both the half-year numbers and the SDAX inclusion, and the Iris² contract has followed suit. The shares have shed roughly 10.8 percent since entering the index. Over the past twelve months, the stock has more than tripled, though it remains well below its 52-week high of €688.00.

The question hanging over the market is whether the rally has simply run too far, too fast. When even a billion-euro contract win fails to attract fresh buyers, it suggests much of the good news was already priced in when the shares peaked in the spring.

The Bull and Bear Case in Tension

For the optimists, the fundamentals remain compelling. The Iris² award is just one component of a swelling order book that also includes the PRISMA Second Generation mission for OHB Italia, announced in July and running through the end of 2031. First-half performance was robust — total output of €628 million against €470 million in the prior-year period — and management has left its 2026 guidance unchanged at €1.4 billion in total output with a margin of 10.5 to 11 percent. Several analysts initiated coverage in early August with price targets ranging from €250 to €360, all above current levels.

The bears, however, point to valuation and technicals. With annualized volatility of 59 percent, OHB is among the most swing-prone stocks in the SDAX. The shares are already approaching their 200-day moving average; a decisive break below that level would be a warning sign that could intensify selling pressure. The risk is that the current weakness marks the beginning of a prolonged consolidation in which investors use every positive headline as an exit opportunity rather than an entry point.

What Happens Next

The near-term catalyst calendar is thin but potentially significant. The regular index review scheduled for September could see OHB promoted to the TecDAX, a prospect that has been floated and would likely draw passive flows. Further concrete details on the Iris² contract — and whether additional analyst coverage or price-target adjustments follow — will also shape sentiment.

The rocket delay at RFA One adds a wildcard. If it proves isolated, the market may well treat it as a minor blemish on an otherwise strengthening order landscape. If it signals broader execution problems, it could feed the bearish narrative that the company's ambitions are running ahead of its operational realities.

For now, OHB presents a study in contrasts: a core satellite business gaining visibility through Europe's most important space programme, a balance sheet freshly fortified with capital, and a rocket subsidiary whose timeline keeps slipping. Whether the shares resume their ascent or enter a deeper correction may ultimately depend on whether the company can convert its growing backlog into the margins and cash flow that the current valuation demands. Until then, this remains a stock for investors with strong nerves and a tolerance for turbulence.